Minimal residual disease (MRD) monitoring by quantitative RT-PCR (RQ PCR) and FISH in chronic myelogenous leukemia (CML) patients treated with STI571 (Gleevec®).

被引：0
|
作者：
Roche, C
Grardel, N
Cornu-Soenen, V
Laï, JL
Roumier, C
Berthaud, P
Chatelain, N
Cosson, A
Facon, T
Preudhomme, C
机构：
[1] INSERM, CHU Lille, U524, Lab Hematol A, F-59045 Lille, France
[2] INSERM, CHU Lille, U524, Lab Cytogenet, F-59045 Lille, France
[3] INSERM, CHU Lille, Lab Hematol A, F-59045 Lille, France
[4] Novartis France, Div Oncol, Paris, France
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2578
引用
收藏
页码：615A / 615A
页数：1
相关论文
共 50 条
  • [21] Analysis of chronic myeloid leukemia (CML) cases with minimal disease after interferon treatment by means of interphase FISH and quantitative RT-PCR
    Tchirkov, A
    Giollant, M
    Briancon, G
    Travade, P
    Tavernier, F
    Tournilhac, O
    Deméocq, F
    Malet, P
    CYTOGENETICS AND CELL GENETICS, 1999, 85 (1-2): : 87 - 87
  • [22] Analytical performance characteristics of a quantitative RT-PCR assay of BCR-ABL for monitoring minimal residual disease in CML
    England, TE
    Wong, P
    Delaney, C
    Fesseha, G
    CLINICAL CHEMISTRY, 2005, 51 : A183 - A183
  • [23] Quantification of residual disease in chronic myeloid leukemia patients treated by interferon using interphase FISH and competitive RT-PCR
    Tchirkov, A
    Giollant, M
    Briancon, G
    Travade, P
    Tournilhac, O
    Demeocq, F
    Kuleshov, N
    Malet, P
    CYTOGENETICS AND CELL GENETICS, 1997, 77 (1-2): : P325 - P325
  • [24] Quantitation of minimal residual disease with real-time quantitative RT-PCR in patients treated with DLI for relapsed CML after BMT
    Schattenberg, A
    Mensink, E
    Schaap, N
    de Witte, T
    BONE MARROW TRANSPLANTATION, 1999, 23 : S46 - S46
  • [25] Multiplex real-time quantitative RT-PCR for monitoring chronic myelogenous leukemia.
    Samoszuk, N
    Tseng, RW
    BLOOD, 1999, 94 (10) : 278B - 278B
  • [26] Minimal residual disease monitoring by quantitative real time-PCR during treatment with STI571 for bcr/abl-positive acute lymphoblastic leukemia.
    Martinelli, G
    Piccaluga, PP
    Malagola, M
    Rondoni, M
    Soverini, S
    Amabile, M
    Pane, F
    Bianchini, M
    Ottaviani, E
    Giannini, B
    Vigna, E
    Bosi, C
    Gaitani, S
    Paolini, S
    Russo, D
    Visani, G
    Fiacchini, M
    Baccarani, M
    BLOOD, 2003, 102 (11) : 245B - 246B
  • [27] Detection of minimal residual disease in chronic myeloid leukemia using a real time quantitative RT-PCR assay
    Bouraoui, S.
    Dhouib, H.
    Boughriba, R.
    Weslati, M.
    Ounissi, D.
    Hazgui, M.
    Dhraief, M.
    Mezabi, S. Regaya
    VIRCHOWS ARCHIV, 2015, 467 : S199 - S199
  • [28] Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement
    S Viehmann
    A Teigler-Schlegel
    J Bruch
    C Langebrake
    D Reinhardt
    J Harbott
    Leukemia, 2003, 17 : 1130 - 1136
  • [29] Prognostic relevance of minimal residual disease (MRD) analysis in BCR-ABL positive acute lymphoblastic leukemia (ALL) patients during Gleevec (STI571) therapy.
    Scheuring, UJ
    Pfeifer, H
    Brueck, P
    Wassmann, B
    Atta, J
    Gschaidmeier, H
    Petershofen, E
    Hoelzer, DF
    Ottmann, OG
    BLOOD, 2001, 98 (11) : 762A - 763A
  • [30] Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement
    Viehmann, S
    Teigler-Schlegel, A
    Bruch, J
    Langebrake, C
    Reinhardt, D
    Harbott, J
    LEUKEMIA, 2003, 17 (06) : 1130 - 1136
12345